Neuroscience company SyncThink has revealed new data indicating traction for its Eye-Sync platform. The system recently was identified by the U.S. Food and Drug Administration for potential future approval.
The brain analytics company revealed 2018 data usage milestones this week that it said reflect a “steep growth trajectory” for the platform. Eye-Sync is intended to aid in the rehabilitation of people after head trauma. Notably, SyncThink has built and currently maintains the world’s largest eye-tracking database, with more than 50,000 patient results.
In its first full year on the commercial market, SyncThink said it received wide adoption from healthcare organizations, professional sports teams (including the Golden State Warriors) and college athletics programs.